Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003–2004

This publication has 13 references indexed in Scilit:

• Trivalent Live Attenuated Intranasal Influenza Vaccine Administered During the 2003–2004 Influenza Type A (H3N2) Outbreak Provided Immediate, Direct, and Indirect Protection in Children
  Pediatrics, 2007
• Strategies for mitigating an influenza pandemic
  Nature, 2006
• Mitigation strategies for pandemic influenza in the United States
  Proceedings of the National Academy of Sciences, 2006
• On estimation of vaccine efficacy using validation samples with selection bias.
  Biostatistics, 2006
• Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial
  Pediatrics, 2005
• Containing Pandemic Influenza at the Source
  Science, 2005
• Assessment of the effectiveness of the 2003-04 influenza vaccine among children and adults--Colorado, 2003.
  2004
• Direct and Total Effectiveness of the Intranasal, Live-Attenuated, Trivalent Cold-Adapted Influenza Virus Vaccine Against the 2000-2001 Influenza A(H1N1) and B Epidemic in Healthy Children
  Archives of Pediatrics & Adolescent Medicine, 2004
• Estimating Efficacy of Trivalent, Cold-adapted, Influenza Virus Vaccine (CAIV-T) against Influenza A (H1N1) and B Using Surveillance Cultures
  American Journal of Epidemiology, 2003
• Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control
  Vaccine, 2000